Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Erythromycin And Paracetamol See April Rises In UK

Pricewatch UK – April 2020

Executive Summary

Erythromycin and paracetamol were among the products with the steepest price rises in the UK in April, as the coronavirus pandemic continued to make its effects felt in the generics market.

You may also be interested in...



Moxonidine Rises Ramp Up In August

Moxonidine topped our table of Biggest Risers for the second month in a row, as UK prices that had doubled in July accelerated even more rapidly in August.

UK Paracetamol Prices Treble Amid Coronavirus Demand

Average UK trade prices for paracetamol more than trebled in March as the coronavirus outbreak took hold, while the antiviral valaciclovir saw an average increase of over 300%.

UAE’s Bioventure Is Looking For Partners To Expand

Having recently added to its biosimilars alliance with Alvotech, Dubai-based Bioventure says it is looking to expand its international reach through further partnerships.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB149898

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel